bluuebunny/crossref_metadata_2025_split huggingface dataset:
• Fentanyl Shortage Brought Errors/• Depakote ER: Easy to Confuse with Depakote (Delayed-Release)/• Computer Systems Should Stop Adding Terminal Zeroes to Drug Strengths and Doses
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again-perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Iron Sucrose Injection
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The April 2001 Formulary monographsare on caspofungin, peginterferon alfa-2b, ziprasidone, 90Y ibritumomab tiuxe-tan, and Abarelix depot. The DUE is on caspofungin.
Dextromethorphan: Neuropathy
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. references direct the reader to the full literature for more comprehensive information prior to patient care decisions.
Lotrel and Glucotrol XL: QD or QID?
Authors: Dunn Eddie , Wolfe Jonathan 
Published: January 2018

Hospital Pharmacy welcomes contributions to this column. Articles originally published in pharmacy department newsletters are reprinted here. Material is selected because of its educational value to pharmacists or because it demonstrates the type of information of interest to newsletter readers. If you wish to have your newsletter material considered for publication in this column, mail a copy to Facts and Comparison, Attn: Journal Editor, Hospital Pharmacy, 111 West Port Plaza, Suite 300, St. Louis, MO 63146-3098.
• Drug Shortages Lead to Medication Errors; •Dispense from the Pharmacy, Not from Central Supply; •Use of Symbols Increases Medication Error Risk
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Ondansetron: Bulimia
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. references direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
•Caution: Packaging of the New IV Bag of Brevibloc (Esmolol) Premixed Injection Could Lead to Errors; •New “Tall Man” Lettering Will Reduce Mix-ups due to Generic Drug Name Confusion; •Extra Caution Needed with U-500 Regular Insulin
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
Ziprasidone
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The June 2001 Formulary monographs are on pantoprazole IV, darbepoetin, voriconazole, bimatoprost ophthalmic solution, and prasterone. The DUE is on pantoprazole.
Etanercept: Congestive Heart Failure
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
•Confusion Possible between Colazal and Clozaril;•Failure to Adjust Dose of Amphotericin B When Route Changed from Oral to IV;•Fentanyl Transdermal System Unsafe in Inexperienced Hands
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.
The Stability of Diluted Vincristine Sulfate Used as a Deterrent to Inadvertent Intrathecal Injection
Authors: Trissel Lawrence A. , Zhang Yanping , Cohen Michael R. 
Published: January 2018

The objective of this study was to evaluate the physical and chemical stability of vincristine sulfate diluted to a variety of concentrations in 0.9% sodium chloride injection and packaged in minibags and 30 mL syringes, to help deter inadvertent intrathecal injection of the drug. Test samples were prepared by diluting vincristine sulfate quantities of 0.5 mg, 1 mg, 2, mg, and 3 mg in 0.9% sodium chloride injection. These quantities were selected to span the range of doses normally expected for this cytotoxic drug. The vincristine was diluted with 0.9% sodium chloride injection in volumes of 25 mL and 50 mL packaged in polyvinyl chloride minibags and to 20 mL packaged in 30 mL polypropylene syringes. Physical and chemical stability evaluations were performed initially and after 1, 3, and 7 days of storage at 4°C followed by an evaluation at 9 days after 2 additional days of storage at a temperature of 23°C. Physical stability was assessed using visual observation in normal light and a high-intensity monodirectional light beam. In addition, turbidity and particle content were measured electronically. Chemical stability of the drug was evaluated by using a stability-indicating high performance liquid chromatographic (HPLC) analytical technique. No physical instability was noted and no unacceptable loss of vincristine sulfate concentration was found in any sample throughout the study period. The use of vincristine sulfate doses diluted in infusion volumes of 0.9% sodium chloride injection and packaged in minibags or in 30 mL syringes to help deter inadvertent intrathecal administration may be performed with no unacceptable physical or chemical instability occurring.
Formoterol Fumarate Inhalation Powder
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The July 2001 Formulary monographs are on ima-tinib mesylate, alemtuzumab, parecoxib sodium, pramlintide acetate, and busesonide modified-release capsules. The DUE is on galantamine.
New Interpretation of JCAHO Standard Bans Open Access to Pharmacy after Hours/Confusion between Occlusal-HP and Ocuflox/0.125 or 0.1 to 5?
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers’ names will be published if desired. ISMP may be contacted at the address shown below.
Safe and Appropriate Use of lodinated Radiographic Contrast Agents: Is There a Reason to Use High-Osmolality lodinated Contrast Agents?
Authors: Martin William R. 
Published: January 2018

The improved safety profile of low-osmolality compared with high-osmolality iodinated radiographic contrast agents supports the use of low-osmolality iodinated contrast agents in patients with a high risk for adverse reactions to contrast agents. Current pressures in the health care industry to minimize costs may warrant the continued use of high-osmolality agents in patients with relatively low risk for contrast reactions. Health-system management and pharmacists should continue to review the clinical and pharmacoeconomic issues surrounding the use of high-osmolality agents, because market factors have caused the prices of high-osmolality agents and second-generation low-osmolality agents to fluctuate. Moreover, the introduction of new agents will continue to change the risk—benefit–cost relationship. Administration guidelines and appropriate patient monitoring are important, because both low-osmolality and high-osmolality agents carry the risk of adverse reactions. Pharmacologic pretreatment to alleviate adverse reactions to contrast agents when high-osmolality agents are used should be encouraged. Pharmacists—in cooperation with diagnostic imaging departments—should ensure that the use of iodinated radiographic contrast agents conforms to accepted guidelines.
Pantoprazole IV
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board called The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2001 Formulary monographs are on almotriptan maleate, crotalidae polyvalent immune fab, drospirenone/ethinyl estradiol, fondaparinux sodium, and alfuzosin. The DUE is on peginterferon alfa-2b.
Venlafaxine: Hot Flashes
Authors: Generali Joyce , Cada Dennis J. 
Published: January 2018

Off-Label Drug Uses This Hospital Pharmacy feature is extracted from Off-Label DrugFacts, a quarterly publication available from Facts and Comparisons. Off-Label DrugFacts is a practitioner-oriented resource for information about specific FDA-unapproved drug uses. This new guide to the literature will enable the health care professional/clinician to quickly identify published studies on off-label uses and to determine if a specific use is rational in a patient care scenario. The most relevant data are provided in tabular form so that the reader can easily identify the scope of information available. A summary of the data—including, background, study design, patient population, dosage information, therapy duration, results, safety, and therapeutic considerations—precedes each table of published studies. References direct the reader to the full literature for more comprehensive information prior to patient care decisions. Direct questions or comments on “Off-Label Drug Uses” to hospitalpharmacy@drugfacts.com .
Confusion between Lantus and Lente Insulins/Serzone and Seroquel Mixups/Coumadin–Avandia Confusion
Authors: Cohen Michael R. 
Published: January 2018

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them in your inservice training programs. Your assistance is required to continue this feature. The reports described here were received through the USP Medication Errors Reporting Program, which is presented in cooperation with the Institute for Safe Medication Practices. If you have encountered medication errors and would like to report them, you may call USP toll-free, 24 hours a day, at 1-800-233-7767 (1-800-23-ERROR). Any reports published by ISMP will be anonymous. Comments are also invited; the writers ‘names will be published if desired. ISMP may be contacted at the address shown below.
Alemtuzumab
Authors: Cada Dennis J. , Levien Terri , Baker Danial E. 
Published: January 2018

Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The September 2001 Formulary monograph topics are telithromycin, trivalent influenza vaccine, drotrecogin alfa, pime-crolimus cream, zoledronic acid, and brimonidine tartrate opththalmic solution. The DUE is on almotriptan maleate.
Contacting Patients with Unclaimed Prescriptions: The Pharmacist's Impact on Drug Therapy Concordance
Authors: Tavitian Sandra M. , Kidder Phyllis A. , Shane Rita 
Published: January 2018

Objectives Nonadherence to medication therapy may lead to poor control of chronic medical conditions and unnecessary utilization of health care services. Prescriptions that are filled but remain unclaimed are a marker for patient non-concordance with their medication regimens. This study evaluated the pharmacist's impact on concordance by contacting patients about their unclaimed prescriptions. Methods Prescriptions that were not picked up within 2 weeks of the date they were filled were reviewed by a pharmacist. Medications used for chronic disease states were targeted. Patients were called and asked a standard set of openended questions about their reasons for failing to pick up the medications. They were also asked if any doses were missed and if they had experienced side effects from the medications. They were counseled on the importance of compliance and encouraged to pick up their prescriptions. Some patients had valid reasons for not picking up their medications. The prescriptions were eventually categorized as “claimed” or “never claimed.” Results During the 29-week study period, there were 177 unclaimed prescriptions for chronic conditions among 141 patients. The pharmacist was able to communicate with 72 patients. From the sample of patients contacted, 45% of patients picked up their prescriptions after our intervention. The proportion of patients who picked up their medications was significantly greater (p < 0.005) when the pharmacist spoke to them, rather than leaving a telephone message. Conclusion The pharmacist can play an important role by educating patients, encouraging them to pick up their medications, and resolving barriers that prevent them from adhering to their drug regimens.